还原型谷胱甘肽对多发性骨髓瘤患者沙利度胺相关的周围神经病变的保护作用

目的探讨还原型谷胱甘肽对多发性骨髓瘤患者应用沙利度胺引起的周围神经病变的临床应用价值。方法 40例多发性骨髓瘤患者,随机分为两组,治疗组给予还原型谷胱甘肽联合沙利度胺及化疗治疗,对照组仅予沙利度胺及化疗治疗,观察两组患者周围神经炎的发生率及发生强度。结果治疗组的周围神经病变发生率为55.0%(11/20),对照组为70.0%(14/20),两组间差异无统计学意义(P0.05);治疗组中患者正中神经、尺神经的神经运动传导速度(MCV)和神经感觉传导速度(SCV)及腓总神经的MCV、腓浅神经的SCV均优于对照组(P0.05)。结论还原型谷胱甘肽可减少多发性骨髓瘤患者因沙利度胺引起的周围神经病变。

Protective effect of reduced glutathione on peripheral neuropathy by thalidomide in multiple myeloma

Objective To explore the clinical application value of reduced glutathione （GSH） to prevent peripheral neuropathy with thalidomide in multiple myeloma, Methods Forty patients of multiple myeloma who got the therapy with thalidomide were randomly divided into two groups, the patients in the treatment group were treated with GSH and thalidomide in combination with chemotherapy, the patients in the control group were treated without GSH. The incidence and occurrence of peripheral neuropathy between the two groups were observed and analyzed to determine the difference. Results The total incidence of peripheral neuropathy in the treatment group was 55.0 % （11/ 20）, while that in the control group was 70.0% （14/20）, there was no significant difference between the two groups（ P 〉 0.05）. The MCV and SCV of median nerve and ulnar nerve, peroneal nerve MCV and superficial peroneal nerve SCV of the treatment group were higher than those of the control group,and the differences were all statistically significant （ P 〈0.05）. Conclusion Use of GSH can reduce the incidence and degree of peripheral neuropathy related to thalidomide.